BACKGROUND: This study evaluated the conjunctival effects of latanoprost and timolol, both of which contain benzalkonium chloride, in patients with primary open-angle glaucoma (POAG), with and without a history of allergic conjunctivitis (AC). METHODS: Two groups of 25 patients with and without a positive history for AC were studied. After a 21-day wash-out period patients were randomized to 14 days treatment with latanoprost or with timolol, in a cross-over fashion. The following parameters were evaluated on days 0 and 14: number of white blood cells, ferning test, conjunctival impression cytology, subjective symptoms, and objective ocular changes. RESULTS: Latanoprost caused: (a) an increase in eosinophils in both groups and reduction i...
Purpose. To assess the efficacy and side effects of 0.005% latanoprost once daily during 3 years of ...
AIM: To explore the effect and mechanism of latanoprost on open-angle glaucoma. <p>METHODS: Totally ...
Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (Tapros®: taflupr...
Tejaswini Walimbe,1 Vidya Chelerkar,2 Purvi Bhagat,3 Abhijeet Joshi,4 Atul Raut4 1Walimbe Eye Clini...
OBJECTIVES: To compare ocular surface changes induced via glaucoma treatment in patients using fixed...
Purpose: The deleterious effects of benzalkonium chloride (BAK) on the ocular surface are well known...
Gregory Katz1, Clark L Springs2, E Randy Craven3, Michela Montecchi-Palmer41Huron Ophthalmology, Yps...
Purpose: To study ocular surface changes induced by topical treatment with prostaglandin analogs c...
WOS: 000337887600001PubMed ID: 25009742Purpose. The aim was to compare the effects of antiglaucoma e...
Background: Topical beta blockers, Timolol and the prostaglandin F2α analogue Latanoprost are the mo...
BACKGROUND: To evaluate the safety and tolerability of Polyquad-preserved Travoprost (PQ-Travopro...
Lauren M Rosin,1 Nicholas P Bell1,2 1Ruiz Department of Ophthalmology and Visual Science, The Univer...
Background: Prolonged use of anti-glaucoma therapy leads to development of ocular surface disease (O...
Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous op...
Bridgitte Shen Lee,1 Ranjan Malhotra,2 Kenneth Sall,3 Brittany Mitchell,4 James Peace5 1Vision Optiq...
Purpose. To assess the efficacy and side effects of 0.005% latanoprost once daily during 3 years of ...
AIM: To explore the effect and mechanism of latanoprost on open-angle glaucoma. <p>METHODS: Totally ...
Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (Tapros®: taflupr...
Tejaswini Walimbe,1 Vidya Chelerkar,2 Purvi Bhagat,3 Abhijeet Joshi,4 Atul Raut4 1Walimbe Eye Clini...
OBJECTIVES: To compare ocular surface changes induced via glaucoma treatment in patients using fixed...
Purpose: The deleterious effects of benzalkonium chloride (BAK) on the ocular surface are well known...
Gregory Katz1, Clark L Springs2, E Randy Craven3, Michela Montecchi-Palmer41Huron Ophthalmology, Yps...
Purpose: To study ocular surface changes induced by topical treatment with prostaglandin analogs c...
WOS: 000337887600001PubMed ID: 25009742Purpose. The aim was to compare the effects of antiglaucoma e...
Background: Topical beta blockers, Timolol and the prostaglandin F2α analogue Latanoprost are the mo...
BACKGROUND: To evaluate the safety and tolerability of Polyquad-preserved Travoprost (PQ-Travopro...
Lauren M Rosin,1 Nicholas P Bell1,2 1Ruiz Department of Ophthalmology and Visual Science, The Univer...
Background: Prolonged use of anti-glaucoma therapy leads to development of ocular surface disease (O...
Nathan M Radcliffe Ophthalmology, New York University, New York, NY, USA Abstract: Glaucomatous op...
Bridgitte Shen Lee,1 Ranjan Malhotra,2 Kenneth Sall,3 Brittany Mitchell,4 James Peace5 1Vision Optiq...
Purpose. To assess the efficacy and side effects of 0.005% latanoprost once daily during 3 years of ...
AIM: To explore the effect and mechanism of latanoprost on open-angle glaucoma. <p>METHODS: Totally ...
Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (Tapros®: taflupr...